Trond Vidar Hansen
Anders Vik
Charles N. Serhan2- 1Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, Oslo, Norway
- 2Department of Anesthesiology, Perioperative and Pain Medicine, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine, Boston, MA, United States
A western type diet and lifestyle play an important role in the development of chronic diseases, yet little insight into the precise cellular and biomolecular mechanisms has emerged. It is known that an unbalanced diet may result in obesity and diabetes. Sufficient amounts and proper balance of omega-6 and omega-3 polyunsaturated fatty acids is key for maintenance of health. The resolution of inflammation is now held to be a biosynthetically actively driven process precisely regulated and controlled by a superfamily of specialized pro-resolving mediators. Specialized pro-resolving mediators are biosynthesized from both omega-6 and omega-3 polyunsaturated fatty acids and are resolution agonists acting on distinct G-coupled protein receptors. These mediators display potent anti-inflammatory and pro-resolving bioactions with EC50-values in the low nanomolar to picomolar range. The protectin (PD) family of specialized pro-resolving mediators is biosynthesized from the two omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and n–3 docosapentaenoic acid (n–3 DPA). All of the PDs display interesting bioactions as anti-inflammatory and pro-resolving agents. This review covers the bioactions, G-coupled protein receptors pharmacology, biosynthesis, and medicinal chemistry of the PD family of specialized pro-resolving mediators with an emphasis on obesity and anti-diabetic effects. In order to enable drug development and medicinal chemistry efforts against these diseases, stereoselective total organic synthesis of each of these mediators is required for confirmation of structure, stereochemical biosynthesis, and their functions. We provide an overview of our ongoing efforts and the current knowledge.
Introduction
Lipid Mediators in the Acute Inflammatory Response: Uncontrolled Inflammation and Neutrophil Responders
Obesity and diabetes are two highly prevalent pathological conditions of western society due to incorrect diet, tobacco use, alcohol consumption, and an increased sedative lifestyle (Leonard, 2008). Among these factors, the general medical opinion is that diet is a significant factor increasing incidence and mortality of these diseases (Leonard, 2008). An elevated intake of western type diet rich in red meat and processed food, i.e., a poor and pro-inflammatory diet, might develop into acute or chronic inflammation (Carrear-Bastos et al., 2011). This type of diet is high in omega-6 and rather low in omega-3 PUFAs (Simopoulos, 2006). Studies of the molecular, cellular and pharmacological processes involved in inflammation have revealed that such PUFAs are biosynthetically transformed to potent oxygenated lipid mediators that participate in the inflammatory processes (Cotran et al., 1999). The acute inflammatory responses are host-protective to contain foreign invaders and in health, are self-limited (Malawista et al., 2008). If uncontrolled, chronic inflammation may result in numerous diseases, including obesity and diabetes (Serhan, 2004). In both diseases, peripheral blood markers of inflammation are present in elevated levels after intake of a pro-inflammatory western type diet (Calder, 2017).
Studies led by Samuelson and co-workers on the biomolecular understanding of inflammation resulted in the identification of PGs, LTs and thromboxanes that act as pro-inflammatory mediators when formed in excess (Samuelsson, 2012). Examples are LTs B4 and C4 that are stereoselectively biosynthesized from the omega-6 PUFA AA in the presence of LOXs, while COXs form PGs (Samuelsson et al., 1987). AA is also involved in the biosynthesis of the anti-inflammatory and pro-resolving lipid mediators named LX A4 (LXA4) and LX B4 (LXB4) (Serhan, 1997). LTs, PGs and LXs act via individual GPCRs and play key roles in the early events and in the initiation of the inflammatory response by activating neutrophils (polymorphonuclear leukocytes, PMNs) (Samuelsson et al., 1987; Serhan, 1997). PMNs are the first cellular responders to the site of inflammation and aim to neutralize and clear foreign invaders. During the inflammatory response the biosynthesis of PGs and LTs occurs within seconds to minutes and increases with time (Figure 1; Samuelsson et al., 1987; Serhan, 1997; Buckley et al., 2014).
Figure 1. The inflammatory response and outline of biosynthetic pathways involving arachidonic acid. TGs, triglycerides; PLPs, phospolipids.
Several drugs have been developed that target chronic conditions and work toward dampening the effects from inflammatory markers. Steroids, such as cortisol, provided the first leads, but later the LTs and PGs have been used as lead compounds for the development of several anti-inflammatory drugs (Samuelsson, 2012). The LXs have also been the topic of drug discovery efforts (Petasis et al., 2005; Fetterman and Zdanowicz, 2009). Examples of anti-inflammatory drugs are the two non-selective COX-inhibitors ibuprofen and acetylsalicylic acid, the selective COX-2 inhibitor celecoxib, the leukotriene-antagonist montelukast and the 5-LOX inhibitor zileuton (Samuelsson, 2012).
Beneficial Roles of Dietary Omega-3 Fatty Acids in Inflammatory Processes. Biosynthesis of Specialized Pro-resolving Mediators and Resolution
The omega-3 PUFAs EPA, n–3 DPA, and DHA, abundant in fatty fish and several dietary supplement products, have been attributed with several health benefits, including prevention of obesity and diabetes (Cotran et al., 1999). These PUFAs are essential as they are produced in only very limited amounts de novo in humans and thus must be obtained from our diets (Simopoulos, 2006; Calder, 2017). The cellular, pharmacological and biochemical modes of actions these PUFAs display in modulating these diseases are still under investigation. Of note, it was believed earlier that the host response was passive (Bannenberg et al., 2005; Serhan and Savill, 2005; Gordon, 2016) during resolution, and that eicosanoids (LT B4, PGs) (Bannenberg et al., 2005; Serhan and Savill, 2005), complement products (Ward, 2010) chemokines, and cytokines directed PMNs to local tissue sites (Medzhitov, 2015) with all of these mediators simply diluting over time within tissues (Figure 2). This dilution would then limit additional PMN recruitment and eventually enabling tissues to restore physiology (Bannenberg et al., 2005). However, numerous studies have shown that the LXs, biosynthesized from AA, function as potent and active stop signals for PMN influx characteristics of SPMs (Takano et al., 1998; Serhan et al., 2000) indicating that the resolution response is a biosynthetically active process (Serhan and Savill, 2005).
Figure 2. Outline of the essential lipid mediator switch involved in the return to homeostasis.
The omega-3 PUFAs EPA and DHA, abundant in fat fish and used in dietary supplements, have been associated with many health benefits (Calder, 2017). SPMs may constitute the molecular basis for such positive claims in a wide range of clinical indications. Evidence has been provided over the last two decades on the detailed cellular and biochemical mechanisms showing that during self-limited inflammatory response a switch in the biosynthesis of pro-resolving SPMs occurs (Figure 2; Levy et al., 2001). This active biosynthesis increases with time. The switch in the biosynthesis of pro-resolving SPM autacoids provides a cellular, biochemical and detailed enzymatic mechanistic explanation on how the resolution of inflammation occurs and completes in order to regain a new homeostasis in contained inflammatory exudates (Figures 2, 3; Bannenberg et al., 2005). The molecular, biochemical and cellular events involved in the return to homeostasis have been coined catabasis (Serhan and Savill, 2005). For a schematic overview, please consult Figure 3. When the resolving secretory phospholipases cPLA2-IID and ZPLA2-III are stimulated (Takano et al., 1998) the PUFAs EPA, DHA and n–3 DPA are released from phospholipids enabling biosynthetic production of SPMs in specific organs (Figure 4; Levy et al., 2001). In exudates, unesterifed omega-3 PUFAs are delivered from blood via edema proteins for enzymatic conversion to SPMs (Kasuga et al., 2008), thus providing novel mechanisms for substrate availability for SPM biosynthesis to terminate further expansion of the cellular exudates (Murakami et al., 2015).
Figure 3. A general outline of the lipid mediator class switch involving SPM biosynthesis from EPA and DHA.
Figure 4. An outline of the biosynthetic formation of specialized pro-resolving mediators and their biosynthetic formation. TGs, triglycerides; PLPs, phospolipids.
Specialized Pro-resolving Mediators Are Resolution Agonists Acting on G-Protein Coupled Receptors
The SPMs display potent nanomolar agonist actions in vivo, that are stereoselective and act as ligands for individual GPCRs (Serhan and Chiang, 2013). The activation of one or several GPCRs induces cellular functions that carry out the potent bioactivities of the SPMs. Initial studies on the receptors for PD1 revealed cell-type specific activity that was also structure dependent (Levy et al., 2007). By using radiolabelled PD1 specific binding toward leukocytes was observed (Marcheselli et al., 2010). The identification that PD1 elicit signaling responses toward GPR37 was very recently reported by Bang et al. (2018). These investigators also reported that GPR37 activation in macrophages increased phagocytosis, altered cytokine release and promoted resolution of inflammatory pain. Table 1 lists the known GPCRs that SPMs activate to evoke resolution of inflammation in vivo in experimental animal models. Hence, it is possible that PD1 has additional receptors on neurons that directly regulate pain signaling.
Table 1. Reported receptors for specialized pro-resolving mediators.
The Protectin Family of SPMs
As mentioned, the resolution of inflammation is now held to be a biosynthetically active process, regulated by biochemical mediators and receptor-signaling pathways governed by SPMs. The Serhan group employed lipid mediator proteomics, metabololipidomics (LC/MS-MS) and cell trafficking in self-limited inflammatory exudates to identify three new families of SPMs (Serhan et al., 2002, 2009; Hong et al., 2003; Dalli et al., 2013, 2014, 2015a,b; Ramon et al., 2016) coined the resolvins (resolution phase interaction products), PDs, and maresins (macrophage mediators in resolving inflammation). Each family is structurally distinct and biosynthesized from the n–3 essential fatty acids EPA, n–3 DPA, or DHA (Figure 5; Serhan et al., 2002, 2009; Hong et al., 2003; Dalli et al., 2013, 2014, 2015a,b; Ramon et al., 2016). PDs belong, together with the LXs, resolvins, maresin, as well as the sulfido-conjugates RCTRs, PCTRs, and MCTRs (maresin conjugates in tissue regeneration), to the super families of mediators (Figure 5). The PDs are structurally unique from the other SPMs because they possess a conjugated triene and their biosynthesis is initiated from the enzymatic production of a 17HpDHA intermediate.
Figure 5. The chemical structures of AA, EPA, DHA, and n–3 DPA and an outline of the individual families of SPMs biosynthesized from these PUFAs.
Pro-resolving and Anti-Inflammatory Actions of Protectins
The protectin family of SPMs have attracted considerable interest from the biomedical community as resolution leads (Serhan, 2014; Fullerton and Gilroy, 2016; Dalli and Serhan, 2018). The precise cellular events, biochemical pathways and molecular mechanisms of the PDs in the resolution of inflammation is of interest in pharmacology and medicinal chemistry enabling drug development (Serhan, 2014; Fullerton and Gilroy, 2016; Dalli and Serhan, 2018). This SPM-subfamily is chemically characterized by two chiral secondary alcohols separated by an E,E,Z-triene moiety. Figure 6 depicts the distinct members of the PD family of SPMs.
Figure 6. Chemical structures of PD1 and the epimer AT-PD1, PD1n–3 DPA, the metabolite 22-OH-PD1, the synthetic analog 22-F-PD1 and PCTR1. The chiral secondary alcohols are positioned at carbon atoms 10 and 17 for all protectins except PCTR1, while the primary alcohol in the metabolite 22-OH-PD1 is at carbon atom 22.
The protectins are biosynthesized from DHA (Serhan et al., 2006; Aursnes et al., 2015) while the n–3 PDs are biosynthesized from n–3 DPA (Primdahl et al., 2017), with the individual biochemical steps presented in detail below. In addition to PMNs, PD1n–3 DPA is produced by macrophages (Serhan et al., 2006; Dalli and Serhan, 2012) and eosinophils (Yamada et al., 2011; Katakura et al., 2015) and its production is reduced in severe asthma patients (Miyata et al., 2013). When PD1 is produced in neural systems, the name NPD1 is used to denote the location of the potent protective actions in retina, brain, and induction of pain (Bazan et al., 2010; Marcheselli et al., 2010; Asatryan and Bazan, 2017). Remarkable potent pro-resolving actions in mice with peritonitis was observed as only 1 ng of PD1 caused a reduction of PMN infiltration by approximately 40% (Serhan et al., 2006) PD1 display potent pro-resolution agonist effects with EC50 ∼ 1 nM and a Kd–value of ∼31 pmol/mg of cell protein (Marcheselli et al., 2010).
AT-PD1
The biosynthetic pathways mediated by human 15-LOX for the omega-6 AA derived LXs and their aspirin-triggered 15-epimeric forms are well established and studied (Serhan, 1997). PD1/NPD1 is biosynthesized predominantly in the 17S configuration by 15-LOX, but aspirin acetylation of COX-2 produces the hydroperoxide intermediate predominantly in the R-configuration at the 17-carbon position. This epimeric hydroperoxide is converted to the 17R epimer 17R-PD1, that is coined AT-PD1 (Serhan et al., 2002, 2011). The R-epimer is longer acting than the S-epimer PD1, most likely due to the stereochemical preference of the eicosanoid oxidoreductase enzymes for S-configured alcohols in the metabolism of oxygenated PUFAs (Serhan et al., 2011). AT-PD1 also display potent pro-resolving and anti-inflammatory actions as well as neuroprotective properties (Serhan et al., 2002, 2011).
The PD1 Further Metabolite 22-OH-PD1 and the Synthetic Analog 22-F-PD1: Medicinal Chemistry Efforts
The further metabolism of PD1 once it is produced locally has not been studied in vivo in humans, but one study has reported a metabolite named 22-OH-PD1 (Figure 6) formed by ω-oxidation at the carbon atom number 22 (C-22) in PD1 (Serhan et al., 2002). This metabolite was prepared by total synthesis (Tungen et al., 2014). In vivo experiments in mice revealed that 22-OH-PD1 displayed potent pro-resolving and anti-inflammatory activities (Tungen et al., 2014). It is likely that additional further metabolic pathways of PD1 are mediated via eicosa oxidoreductases in the same way as for some of the other SPMs (Serhan and Petasis, 2011), although further studies are needed. The potent in vivo pro-resolution actions in the nanomolar range toward efferocytosis and phagocytosis that 22-OH-PD1 displayed spurred our interest in preparing the synthetic analog 22-F-PD1 depicted in Figure 6 (Tungen et al., 2018). When administered via intraperitoneal injection at 100 ng/mouse following Escherichia coli infection, 22-F-PD1 reduced PMN recruitment, enhanced macrophage phagocytosis and reduced bacterial load at similar levels to PD1 (Tungen et al., 2018). Overall, these results verified that the synthetic analog and putative medicinal chemistry agent 22-F-PD1 exhibited both potent anti-inflammatory and pro-resolving actions similar to native PD1. Macrophage phagocytosis and efferocytosis are both key pro-resolving biological actions of interest in drug discovery and clinical development (Serhan et al., 2002).
The Novel Protectin PD1n–3 DPA
Recently, Dalli, Colas and Serhan in Boston, United States demonstrated that n–3 DPA is also a substrate for the biosynthesis of potent bioactive mediators that each correspond to the novel families of SPM (Dalli et al., 2013). While appreciated as an intermediate in omega-3 PUFA biosynthesis in humans, it is interesting that this PUFA is also a precursor to SPMs with 22 carbons and five double bonds (Dalli et al., 2013; Aursnes et al., 2014a). These n–3 immunoresolvents belong (Figure 5) to the three sub-families resolvinsn–3 DPA, PDn–3 DPA, and maresinn–3 DPA each demonstrating potent pro-resolving actions as identified in human subjects (Aursnes et al., 2014a; Markworth et al., 2016; Gobbetti et al., 2017; Hansen et al., 2017). To obtain further evidence for the complete structure of PD1n–3 DPA it was essential to assess that the synthetic material carried the potent biological actions described for PD1n–3 DPA, see below for a discussion on its synthesis (Aursnes et al., 2014a). Administration of synthetic material using 10 ng per mouse significantly reduced neutrophil recruitment during peritonitis following zymosan A challenge (Aursnes et al., 2014a). These bioactions were comparable to those displayed by PD1. Moreover, synthetic material of PD1n–3 DPA stimulated human macrophage phagocytosis and efferocytosis in the pico- to nanomolar range. Overall, these results verified that PD1n–3 DPA exhibited both potent anti-inflammatory and pro-resolving actions, confirming the potent immunoresolvent properties of this SPM (Aursnes et al., 2014a). Potent protective bioactions for PD1n–3 DPA and RvD5n–3 DPA were demonstrated in mouse colitis and in reducing human PMN adhesion to endothelium (Gobbetti et al., 2017). In another recent study, PD1n–3 DPA promotes resolution of neuroinflammation and arrests epileptogenesis potently due to a marked delay in the neuroinflammatory response (Frigerio et al., 2018). These studies were also the first to report that PD1n–3 DPA regulates neuroinflammation (Frigerio et al., 2018). Recently Dalli and co-workers found that the biosynthetic pathway of the n–3 DPA PDs regulated the differentiation of human monocytes, altering macrophage phenotype, efferocytosis, and bacterial phagocytosis (Pistorius et al., 2018).
Protectin Conjugates in Tissue Regeneration: PCTR1, PCTR2 and PCTR3
In 2014 and 2015 three new classes of SPMs were discovered and elucidated that carry potent tissue regenerative properties and posses anti-inflammatory and pro-resolving bioactions (Dalli et al., 2013, 2014). In Figure 6 the chemical structure of PCTR1 is depicted, and this novel SPM belongs to the novel peptide-conjugated PDs that contain a sulfido-bond at the carbon atom 16 and were identified from self-resolving E. coli infections in mice and in human spleen. The biosynthesis is presented below. Enzymatic conversion of PCTR1 in the presence of γ-glutamyl transpeptidase produces PCTR2 and dipeptidase actions yield PCTR3 (Figure 7; Dalli et al., 2014).
Figure 7. Enzymatic conversion of PCTR1 produces PCTR2 and PCTR3.
PCTR1 enhances resolution of infectious inflammation and is produced by human M2 macrophages (Dalli et al., 2015b). In addition, PCTR1 promoted human monocyte and macrophage migration potently and dose-dependently in the 0.001–10 nM range (Dalli et al., 2015b). Furthermore, PCTR1 increased macrophage and monocyte migration, enhanced macrophage efferocytosis, and accelerated tissue regeneration in planaria (Dalli et al., 2015b). It was also reported that PCTR1 is temporally regulated during self-resolving infection. At the peak of inflammation, PCTR1 enhanced macrophage recruitment and phagocytosis of E. coli, decreased PMN infiltration, and counter-regulated inflammation-initiating lipid mediators, including PGs (Dalli et al., 2015b). These findings demonstrated that PCTR1 is a potent monocyte- and macrophage-agonist regulating key anti-inflammatory and pro-resolving processes during bacterial infection.
Protectins in Obesity and Diabetes
As mentioned, a pro-inflammatory western type diet results in an increased level of inflammatory cellular and biomolecular markers, including those biosynthesized from omega-6 and omega-3 PUFAs (Simopoulos, 2006). An expansion of adipose tissue mass associated with a low-grade type of inflammation has been observed with an excess intake of diet and nutrition. This chronic and unresolved inflammation of adipose tissue is harmful and may result in diabetes, insulin resistance and non-alcoholic fatty liver disease, all increasing maladies in western societies (Clària et al., 2017). White adipose tissue plays essential roles in balancing metabolic and energy homeostasis (Clària et al., 2017). This balance is affected by AA, EPA, and DHA. In this setting, Clària and co-workers reported the first investigations on SPM biosynthesis in white adipose tissues given elevated levels of EPA and DHA (Gonzales-Periz et al., 2006, 2009; Clària et al., 2017). These studies showed that dietary amplification of DHA results in increased biosynthesis of PD1 and its precursor 17S-HpDHA (Gonzales-Periz et al., 2006), enzymatically reduced in vivo to 17S-HDHA (Serhan and Petasis, 2011). Using a transactivation assay, 17S-HDHA was shown to be a PPARγ-agonist (Gonzales-Periz et al., 2006). This finding is of interest since several PPARγ-agonists, such as the glitazones, have been developed as anti-diabetic drugs (Gonzales-Periz et al., 2006; Clària et al., 2017). Clària and co-workers also demonstrated that administration of DHA diminished the presence of pro-inflammatory PGs and LT B4 (LTB4) (Gonzales-Periz et al., 2006). Synthetic 17-HDHA stopped genotoxic and oxidative damage in hepatocytes and diminished 5-LOX expression in macrophages. In further studies, these authors reported that the biosynthetic formation of SPMs was severely deregulated in inflamed white adipose tissues as well as in obese mice (Gonzales-Periz et al., 2009). PD1 and RvD1 were reported to be the dominant DHA-derived SPMs based on LC/MS-MS metabololipidomic analyses. They also reported that reduced insulin resistance was observed in white adipose tissues, observations that were in parallel with initiation of phosphorylation of adenosine monophosphate and adiponectin, important regulators of systemic energy balance (Gonzales-Periz et al., 2009).
A skewed biosynthetic process was also observed when these investigators used white adipose tissue from patients with peripheral vascular diseases. In these patients the inflammatory status of white adipose tissue is severely altered (Clària et al., 2013). Within the setting of obesity and diabetes these observations could be due to the diminished tissue levels of omega-3 PUFAs since it has been reported that an increased intake of omega-3 PUFAs enhance SPM biosynthesis (Mas et al., 2012). The reduced level of SPMs quantified could also be explained by an enhanced catabolism or metabolism followed by conversion to further inactive metabolites of SPMs. Interestingly, in obese adipose tissue the enzyme eicosanoid oxidoreductase (15-PG-dehydrogenase) is markedly up-regulated (Gonzales-Periz et al., 2009). This enzyme is involved in the metabolic formation of 17-oxo-RvD1 and 7-oxo-RvD2 from RvD1 and RvD2 (Serhan and Petasis, 2011), respectively, that also occurs in white adipose tissue (Clària et al., 2012). The enzyme soluble epoxide hydrolase 2 (sEH) converts epoxides (Haeggström and Funk, 2011; Serhan and Petasis, 2011), some of which are intermediates in PD biosynthesis, formed from EPA and DHA, into diols with lower pro-resolving and anti-inflammatory properties (Haeggström and Funk, 2011; Serhan and Petasis, 2011). The enzyme sEH is found invariably overexpressed in obese mice (Lopez-Vicario et al., 2015). Overall, the studies from Clària et al. (2017) showed that an unbalanced level of SPMs are directly connected to insufficient tissue resolution in both in vitro and in vivo models of diabetes and obesity.
Of interest, Kuda et al. (2016) reported the isolation and characterization of new DHA-derived fatty acid esters of hydroxy fatty acids present in both serum and white adipose tissue after supplementation with DHA. LC/MS-MS results supported the assigned structures without information on the absolute configurations of the compounds. They performed experiments using mice as well as serum from obese patient with diabetes. The novel compound named 13-DHAHLA showed anti-inflammatory properties at much higher concentrations than SPMs (Kuda et al., 2016). These authors also found that 13-DHAHLA hindered the increase in several pro-inflammatory markers, such as interleukin-6, tumor necrosis factor-α, and PGs. In addition, 13-DHAHLA enhanced phagocytosis in zymosan A induced in an in vitro bone marrow derived macrophage assay (Kuda et al., 2016). For the assignment of absolute configuration of these branched DHA esters of hydroxyl substituted fatty acids, stereoselective total synthesis will be required. With synthetic material in hand, investigations toward which GPCR(s) these novel compounds activate, but also thorough in vivo experiments can be performed toward elucidation of any pro-resolving and anti-inflammatory activities these compounds may display.
An isomer of PD1, named protectin DX (PDX), see below and Figure 8 for structure, has been confirmed formed and isolated from white adipose tissue (White et al., 2014). This DHA-derived compound has been reported to alleviate insulin resistance in db/db mice (White et al., 2014, 2015). Of note, PDX did not resolve white adipose tissue inflammation (White et al., 2014). However, in vivo studies with mice showed that both PD1 and PDX were able to modulate PPARγ transcriptional activity (White et al., 2015).
Figure 8. Biosynthesis of PD1, PDX, and isomers formed in vivo.
Structural Elucidation and Determination of Absolute Configuration Using Biosynthetic and Synthetic Studies
In order to elucidate the complete structure of PD1 the correct absolute configuration and olefin geometry had to be determined for this potent SPM. Efforts from the Serhan research team on the biosynthesis of PD1 allowed the complete structural assignment of PD1 (Serhan et al., 2006). Experiments using isotopic oxygen incorporation and acid alcohol trapping products provided LC/MS-MS data that supported the involvement of an epoxide intermediate (Figure 8; Serhan et al., 2006).
The detailed and stepwise biosynthesis of PD1 has now been established as depicted in Figure 8 (Serhan et al., 2006; Aursnes et al., 2015). The enzyme 15-LOX type I functions as a 17-lipoxygenase (Haeggström and Funk, 2011) and forms the 16S,17S-configured epoxide named 16S,17S-ePD. Hydrolysis of this epoxide in a regio- and stereoselective manner at the C-10 position results in the formation PD1. Water attack occurs most likely via a transient allylic carbocation specie, see Figure 8, since the thermodynamically less stable 11E,13E,15Z-configured triene is formed, and not the chemically more stable 11E,13E,15E triene. Moreover, the S-configuration at C17 is not altered (Serhan et al., 2006; Aursnes et al., 2015). The formation of the 17R-HpDHA stereoisomer has been observed in the presence of aspirin and recombinant isolated COX-2 enzyme (Serhan et al., 2002, 2011), that results in the formation of the 17R-epimer of PD1, coined aspirin triggered protectin D1 (AT-PD1). This biosynthetic pathway occurs most likely via a 16R,17R-configurated epoxide intermediate named ePD. Later direct evidence that 16S,17S-ePD is in fact the true intermediate in the biosynthesis of PD1 was provided by Serhan, Hansen and co-workers (Aursnes et al., 2015). These biosynthesis studies were performed using 16S,17S-ePD, stereoselectively prepared by organic synthesis, that confirmed that this epoxide was converted into PD1 in human macrophages (Aursnes et al., 2015). The double LOX product 10,17-diHDHA, named PDX, is biosynthetically produced by two sequential oxygen insertion steps followed by reduction of the 15-LOX produced hydroperoxide-intermediate, affords 10S,17S-diHDHA (Serhan et al., 2006). PDX is an isomer of PD1 and has several reported bioactions relevant for diabetes and obesity (White et al., 2014, 2015). PDX has also been subjected to other biological investigations (Masterson et al., 2015; Stein et al., 2016; Fonseca et al., 2017; Körner et al., 2018). The other isomers of PD1 investigated were reported to possess significant lower potent pro-resolving actions (Serhan et al., 2006). It has recently been demonstrated that PCTR1 is also biosynthesized directly from 16S,17S-ePD (Ramon et al., 2016). Regarding the biosynthesis of the congener PD1n–3 DPA the epoxide named 16S,17S-ePDn–3 DPA has been shown to be an essential biosynthetic intermediate involved in the formation of PD1n–3 DPA in human neutrophils (Primdahl et al., 2017). This epoxide is able to inhibit human neutrophils LTB4 production and that an yet unidentified hydrolytic enzyme converts 16S,17S-ePDn–3 DPA into PD1n–3 DPA (Primdahl et al., 2017).
Reported Total Synthesis of PD1
As of today, the exact structural elucidation of SPMs using LC/MS-MS based metabololipidomics is necessary to establish the exact structure of the endogenously formed bioactive products (Chiang and Serhan, 2017), since only pico- to nanogram amounts of biosynthetic material are formed in vivo. Total syntheses of PD1 have been reported by four research groups (Ogawa and Kobayashi, 2011; Petasis et al., 2012; Aursnes et al., 2014b; Rodriguez and Spur, 2014), but only two groups have used synthetic and authentic material for matching experiments using LC/MS-MS multiple reaction monitoring (MRM). We want to emphasize that such efforts are of vitally importance, since the PDs as well as the other SPMs, display very potent agonist actions toward individual GPCRs in a stereochemically defined manner (Serhan and Petasis, 2011; Chiang and Serhan, 2017). The structural elucidation and physiologic functions of the SPM receptors have recently been reviewed (Chiang and Serhan, 2017). An outline of the different total syntheses of PD1 is presented below.
Kobayashi and Ogawa’s Synthesis of PD1
Ogawa and Kobayashi (2011) disclosed the first total organic synthesis of PD1, which included a Z-selective Wittig reaction and a Suzuki-cross coupling as key steps (Figure 9). These authors prepared the iodide-aldehyde fragment 1 in several steps and then reacted 1 with the ylide of 2 in a Z-selective Wittig reaction to afford, after several other synthetic steps, the ester 3. This ester was subjected to a Suzuki-Miyaura cross-coupling reaction with boron-compound 4 affording compound 5 with the C22 carbon skeleton of PD1 in place. Deprotection of 5 was followed by basic hydrolysis that yielded PD1 (Ogawa and Kobayashi, 2011).
Figure 9. Outline of Kobayashi and Ogawa’s synthesis of PD1.
The Petasis Synthesis of PD1
The first synthesis and assignment of PD1 was reported by Serhan et al. (2006). These efforts also provided synthetic stereoisomers. Biological evaluations of PD1 and its synthetic stereoisomers provided useful information on structure-functions. For the stereochemical assignment Petasis et al. (2012) reported their synthesis in details in 2012, although synthetic PD1 as well as isomers were made available for biological studies from this group much earlier (Serhan et al., 2006). The Petasis synthesis utilized a Sonogashira cross coupling reaction to make the C22 carbon skeleton (Figure 10). The precursor 6 was reacted with 7 using this cross-coupling reaction to yield 8. Of note, the commercially available starting material R-glycidol gave rise to both 6 and 7 (Petasis et al., 2012).
Figure 10. Outline of Petasis and co-workers synthesis of PD1.
In order to obtain a Z-selective reduction of the conjugated alkyne 8 and to establish the correct Z-geometry of the double bond at C11-C12 (Serhan et al., 2006; Petasis et al., 2012), deprotection of the TBS-groups was first performed, thenthe authors used the Boland reduction reaction on 8 that was followed by basic hydrolysis, which furnished PD1. In addition, several isomers of PD1 were synthetized by the same research group. These isomers proved to be less potent pro-resolvents; however these studies provided useful information on structure-function relationships of PD1. The synthetic material was matched with endogenously formed PD1 and found to be identical (Serhan et al., 2006; Petasis et al., 2012).
The Hansen Synthesis of PD1
A highly stereoselective synthesis of PD1 was published in 2014 (Aursnes et al., 2014b), mainly by using Evans-Nagao aldol-, Z-selective Wittig-, and Sonogashira-reactions (Figure 11). The main fragments were the terminal alkyne 6a, the aldehyde 9 and the Wittig-salt 11. The total synthesis of PD1 was performed in only eight linear steps from aldehyde 9. Commercially available pyridinum-1-sulfonate was used for making aldehyde 9. Further on, the aldehyde 9 was reacted in an Evans-Nagao aldol reaction that was followed by protection of the secondary alcohol and removal of the auxiliary to afford the intermediate 10 with high stereoselectivity. Then compound 10 was reacted with the corresponding ylide of the Wittig-salt 11 to yield the tetraene ester 12. The alkyne 6a was reacted with 12 in a Sonogashira cross-coupling reaction to afford 13 with the whole carbon skeleton of PD1. Deprotection of 13 and a Z-selective Lindlar reduction gave the correct Z-geometry of double bond at C15-C16. Saponification and acidic work-up furnished PD1. The synthetic material was matched with endogenously formed PD1 and found to be identical and with high chemical purity and stereochemical integrity (Aursnes et al., 2014b). The difference between alkyne 6, used by the Petasis-group, and alkyne 6a is the protection group.
Figure 11. Outline of Hansen and co-workers synthesis of PD1.
Spur and Rodriguez Synthesis of PD1
Rodriguez and Spur (2014) reported their total synthesis of PD1 that also relied on the Sonogashira cross-coupling reaction with the terminal alkyne 6a (Figure 12). Conversion of commercially available acetal-protected D-ribose gave 14 that was converted into alkyne 6a using a different synthetic route than reported by Petasis and co-workers. The ylide of Wittig salt 11 was reacted with the aldehyde 15 in a Z-selective Wittig-reaction to give intermediate 16. This intermediate was transformed into the vinylic iodide 7 (Figure 12). Finally, fragments 6a and 7 were reacted using the Sonogashira reaction to give 13 that completed the C22 carbon-chain of PD1. The last steps included deprotection of 13 and a Z-selective alkyne reduction using the Boland protocol as well as an ester hydrolysis that gave PD1 (Rodriguez and Spur, 2014).
Figure 12. Outline of Spur and Rodriguez’ synthesis of PD1.
Summary and Future Directions for SPM Therapy in Obesity and Diabetes
The cardinal signs of inflammation: calor, rubor, tumor, dolor, and functio laesa are physiologically mediated by chemical mediators, such as the PGs, and are effectively controlled by traditional NSAIDs (Vane and Botting, 2001). These drugs give unwanted side effects. Given the increase in the inflammation-associated diseases obesity and diabetes it is paramount that new treatments and mechanisms are sought to control excessive inflammation and collateral tissue damage created by excessive PMN and their swarming in all organs (Cotran et al., 1999). Evidence for active endogenous resolution programs and novel resolution mediators holds promise for new therapeutic approaches that would not be immunosuppressive, but rather serve as immunoresolvents and pro-resolving mediator agonists stimulating resolution (Morris et al., 2009; Serhan, 2014; Perretti, 2015; Serhan et al., 2015; Duvall and Levy, 2016; Fullerton and Gilroy, 2016; Serhan, 2017; Vik et al., 2017; Dalli and Serhan, 2018). While current treatments for inflammation can be effective, many of these can eventually become immunosuppressive, opening opportunities for infection.
The distinct properties of EPA, DHA and n–3 DPA exhibits to form pro-resolving lipid mediators may, at least in part, explain the established health effects associated with these omega-3 PUFAs. The biosynthetic pathways of these potent lipid mediators may also explain some of the positive effects of aspirin, since COX-2 in the presence of aspirin biosynthesize metabolically longer lasting epimers of the individual SPM (Serhan and Petasis, 2011; Serhan et al., 2011). These epimers also display potent pro-resolving and anti-inflammatory properties. The different families of SPMs display high structural complexity due to the presence of several stereogenic centers, both in the form of chiral, secondary alcohols and conjugated E- and Z-double bonds, reflecting their biochemical origins, functions and stereospecific bioactions toward individual GPCRs. Hence, acquired knowledge and distinct care must be exercised when working with SPMs. Failure of such diligent operations will not reveal the correct and exciting chemical structures or the potent bioactions that SPMs possesses as resolution agonists. Elucidating the role of PUFAs as precursors and their enzymatic oxygenated products at the cellular and molecular level in health is of current interest (Serhan, 2017). As of today, approximately 80 biologically active DHA-derived metabolites have been described with various biological roles. It is important to emphasize that as of today only the endogenous SPMs, such as the PDs, display both potent pro-resolving and anti-inflammatory bioactions in vivo in the low nanomolar range. Hence, the PDs are therefore among the most exciting small molecules currently under investigations toward drug development based on resolution of inflammation (Gilroy et al., 2004; Morris et al., 2009; Serhan and Petasis, 2011; Tabas and Glass, 2013; Corminboeuf and Leroy, 2014; Perretti, 2015; Serhan et al., 2015; Duvall and Levy, 2016; Serhan, 2017; Vik et al., 2017). PDs display high structural complexity due to the presence of several stereogenic centers, both in the form of chiral, secondary alcohols and conjugated E- and Z-double bonds reflecting their biochemical origins, functions and stereospecific bioactions toward individual GPCRs (Duvall and Levy, 2016). Hence, care must be exercised when working with these SPMs as resolution agonists or as pharmacological biotemplates toward drug development targeting diabetes and obesity (Tabas and Glass, 2013).
The vast majority of approved drugs have been developed to inhibit, block or antagonize specific biological pathways involved in inflammatory conditions (Vane and Botting, 2001). Hence, the inflammatory mechanisms have become central to several diseases, including obesity and diabetes. The detailed biochemical, genetic, molecular, and cellular mechanisms behind the biology of resolution of inflammation has resulted in a new paradigm in our understanding of the inflammatory process. With the appreciation and growing understanding of these intervening mechanisms drugs within “Resolution Pharmacology” will be of interest. Examples of such candidates may be synthetic small molecular mimetics (Corminboeuf and Leroy, 2014; Vik et al., 2017) exhibiting pro-resolution and anti-inflammatory GPCR agonistic properties against obesity and diabetes (Oh and Olefsky, 2016). Moreover, activators of SPM biosynthesis or inhibitors of eicosanoid oxidoreductase (15-PG-dehydrogenase) may also be part of the potential future within the “Resolution Pharmacology” pharmacopeia. Of significance, SPMs are very potent GPCR agonists and approximately 40% of all approved drugs activate this receptor class. Based on the drug development efforts that pro-inflammatory PGs and LTs have resulted in, combined with an increasingly number of receptors identified, future drug development efforts should be facilitated (Gilroy et al., 2004; Tabas and Glass, 2013; Corminboeuf and Leroy, 2014; Duvall and Levy, 2016; Vik et al., 2017). However, such future endeavors depends, similar to past drug development successes based on pro-inflammatory mediators and their biological roles (Samuelsson, 2012), on basic biomedical research. We envision that the development of “Resolution Pharmacology” as well as exciting new findings from basic research related to SPMs will continue to evolve and enable innovative approaches for treating obesity and diabetes.
Author Contributions
All authors contributed to the writing of the manuscript and had gave approval to the final version of the manuscript.
Funding
Generous funding to TH (KOSK 197708, KOSK II 207053, BIOTEK2021 224811, and FRIPRO-FRINATEK 230470) from The Norwegian Research Council is very appreciated. CS was supported by the National Institutes of Health GM Grant PO1GM095467 and continuous financial support is gratefully acknowledged.
Conflict of Interest Statement
CS has filed patents on SPMs and related compounds, licensed for clinical development, and his interests are reviewed and managed by BWH and Partners HealthCare in accordance with their conflict of interest policies.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The reviewer HA declared a past co-authorship with one of the authors to the handling Editor.
Acknowledgments
Dr. Nan Chiang is gratefully acknowledged for skillful assistance in making Figure 2. We want to thank current and past co-workers in Boston and Oslo for fruitful collaborations and in particular their experimental and methodological efforts. TH is also thankful for a Leiv Eriksson travel grant from The Norwegian Research Council enabling a sabbatical period with CS.
Abbreviations
AA, arachidonic acid; COX, cyclooxygenase; DHA, docosahexaenoic acid; n–3 DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; ePD, epoxide biosynthesized from DHA and an intermediate in protectin D1 biosynthesis; ePDn–3 DPA, epoxide biosynthesized from n–3 DPA and an intermediate in protectin D1 biosynthesis; GPCR, G-protein coupled receptor; LC/MS-MS, liquid chromatography tandem mass spectrometry; LM, lipid-derived mediators; LOX, lipoxygenase; LT, leukotriene; LX, lipoxin; LXA4, lipoxin A4 (5S, 6R, 15S-trihydroxy-eicosa-7E, 9E, 11Z, 13E-tetraenoic acid); LXB4, lipoxin B4: (5S, 14R, 15S-trihydroxy-eicosa-6E, 8Z, 10E, 12E-tetraenoic acid); Maresin, macrophage-derived resolution mediator of inflammation; MaR1, maresin 1 (7R, 14S-dihydroxy-docosa-4Z, 8E, 10E, 12Z, 16Z, 19Z-hexaenoic acid); MCTRs, maresin conjugates in tissue regeneration; PCTR, protectin conjugates in tissue regeneration; PD, protectin; PD1, protectin D1 (10R, 17S-dihydroxy-docosa-4Z, 7Z, 11E, 13E, 15Z, 19Z-hexaenoic acid), also named neuroprotectin D1 (NPD1); PD1n–3 DPA, PD1n–3 DPA biosynthesized from n–3 DPA (10R, 17S-dihydroxy-docosa-7Z, 11E, 13E, 15Z, 19Z-pentaenoic acid); PG, prostaglandin; PLP, phospolipid; PMN, polymorphonuclear leukocyte; PUFA, polyunsaturated fatty acid; RCTRs, resolvin conjugates in tissue regeneration; Rv, resolvin, bioactive omega-3 derived resolution phase interaction products; sEH, soluble epoxide hydrolase; SPM, specialized pro-resolving mediators; TG, triglyceride.
References
Asatryan, A., and Bazan, N. G. (2017). Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection. J. Biol. Chem. 292, 12390–12397. doi: 10.1074/jbc.R117.783076
Aursnes, M., Tungen, J. E., Vik, A., Colas, R., Cheng, C.-Y. C., Dalli, J., et al. (2014a). Total synthesis of the lipid mediator PD1n–3 DPA: configurational assignments and anti-inflammatory and pro-resolving actions. J. Nat. Prod. 77, 910–916. doi: 10.1021/np4009865
Aursnes, M., Tungen, J. E., Vik, A., Dalli, J., and Hansen, T. V. (2014b). Stereoselective synthesis of protectin D1: a potent anti-inflammatory and proresolving lipid mediator. Org. Biomol. Chem. 12, 432–437. doi: 10.1039/c3ob41902a
Aursnes, M., Tungen, J. E., Colas, R. A., Vlasakov, I., Dalli, J., Serhan, C. N., et al. (2015). Synthesis of the 16S,17S-epoxyprotectin intermediate in the biosynthesis of protectins by human macrophages. J. Nat. Prod. 78, 2924–2931. doi: 10.1021/acs.jnatprod.5b00574
Bang, S., Xie, Y.-K., Zhang, Z.-J., Wang, Z., Xu, Z.-Z., Ji, R.-R., et al. (2018). GPR37 regulates macrophage phagocytosis and resolution of inflammation pain. J. Clin. Invest. 128, 3568–3582. doi: 10.1172/JCI99888
Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., et al. (2005). Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345–4355. doi: 10.4049/jimmunol.174.7.4345
Bazan, N. G., Calandria, J. M., and Serhan, C. N. (2010). Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J. Lipid Res. 51, 2018–2031. doi: 10.1194/jlr.R001131
Buckley, C. D., Gilroy, D. W., and Serhan, C. N. (2014). Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40, 315–327. doi: 10.1016/j.immuni.2014.02.009
Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem. Soc. Trans. 45, 1105–1115. doi: 10.1042/BST20160474
Carrear-Bastos, P., Fontes-Villalba, M., O’Keefe, J. H., Lindeberg, S., and Cordain, L. (2011). The western diet and lifestyle and diseases of civilization. Res. Rep. Clin. Card 2, 15–35. doi: 10.2147/RRCC.S16919
Chiang, N., and Serhan, C. N. (2017). Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol. Aspects Med. 58, 114–129. doi: 10.1016/j.mam.2017.03.005
Clària, J., Dalli, J., Yacoubain, S., Gao, F., and Serhan, C. N. (2012). Resolvin D1 and Resolvins D2 govern local inflammatoru tone in obese fat. J. Immunol. 189, 2597–2605. doi: 10.4049/jimmunol.1201272
Clària, J., Lopez-Vicario, C., Rius, B., and Titos, E. (2017). Pro-resolving actions in adipose tissue biology. Mol. Aspects Med. 58, 83–92. doi: 10.1016/j.mam.2017.03.004
Clària, J., Nguyen, B. T., Madenci, A. L., Ozaki, C. K., and Serhan, C. N. (2013). Diverstiy of lipid mediators in human adipose tissue depots. Am. J. Cell Physiol. 304, C1141–C1149. doi: 10.1152/ajpcell
Corminboeuf, O., and Leroy, X. (2014). FPR2/ALXR agonists and the resolution of inflammation. J. Med. Chem. 58, 537–559. doi: 10.1021/jm501051x
Cotran, R. S., Kumar, V., and Collins, T. (eds). (1999). Robbins Pathologic Basis of Disease. Philadelphia, PA: W.B. Saunders Co.
Dalli, J., and Serhan, C. N. (2018). Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. Br. J. Pharmacol. doi: 10.1111/bph.14336 [Epub ahead of print].
Dalli, J., Chiang, N., and Serhan, C. N. (2014). Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proc. Natl. Acad. Sci. U.S.A. 111, E4753–E4761. doi: 10.1073/pnas.1415006111
Dalli, J., Chiang, N., and Serhan, C. N. (2015a). Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat. Med. 21, 1071–1075. doi: 10.1038/nm.3911
Dalli, J., Ramon, S., Norris, P. C., Colas, R. A., and Serhan, C. N. (2015b). Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways. FASEB J. 29, 2120–2136. doi: 10.1096/fj.14-268441
Dalli, J., Colas, R. A., and Serhan, C. N. (2013). Novel n–3 immunoresolvents: structures and actions. Sci. Rep. 3:1940. doi: 10.1038/srep01940
Dalli, J., and Serhan, C. N. (2012). Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120, e60–e72. doi: 10.1182/blood-2012-04-423525
Duvall, M. G., and Levy, B. D. (2016). DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. Eur. J. Pharmacol. 785, 144–155. doi: 10.1016/j.ejphar.2015
Fetterman, J. W. Jr., and Zdanowicz, M. M. (2009). Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am. J. Health Syst. Pharm. 66, 1169–1179. doi: 10.2146/ajhp080411
Fonseca, F. C., Orlando, R. M., Turchetti-Maia, R. M., and de Francischi, J. N. (2017). Comparative effects of the omega3 polyunsaturated fatty acid derivatives resolvins E1 and D1 and protectin DX in models of inflammation and pain. J. Inflamm. Res. 10, 119–133. doi: 10.2147/JIR.S142424
Frigerio, F., Pasqualini, G., Craparotta, I., Marchini, S., van Vliet, E. A., Foerch, P., et al. (2018). n-3 docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. Brain 141, 3130–3143. doi: 10.1093/brain/awy247.
Fullerton, J. N., and Gilroy, D. W. (2016). Resolution of inflammation: a new therapeutic frontier. Nat. Rev. Drug Discov. 15, 551–567. doi: 10.1038/nrd.2016.39
Gilroy, D. W., Lawrence, T., Perretti, M., and Rossi, A. G. (2004). Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3, 401–406. doi: 10.1038/nrd1383
Gobbetti, T., Dalli, J., Colas, R. A., Canova, D. F., Aursnes, M., Bonnet, D., et al. (2017). Protectin D1n–3 DPA and resolvin D5n–3 DPA are effectors of intestinal protection. Proc. Natl. Acad. Sci. U.S.A. 114, 3963–3968. doi: 10.1073/pnas.1617290114
Gonzales-Periz, A., Horillo, R., Ferre, N., Gronert, K., Dong, B., Moran-Salvador, E., et al. (2009). Obesity-induced insulin resistance and hepatic steatosis are alleviated by ?-3 fatty acids: a role for resolvins and protectins. FASEB J. 23, 1946–1957. doi: 10.1096/fj.06-6250fje
Gonzales-Periz, A., Planaguama, A., Gronert, K., Miquel, R., Lopez-Parra, M., Titos, E., et al. (2006). Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy DHA. FASEB J. 20, E1844–E1855. doi: 10.1096/fj.06-6250fje
Gordon, S. (2016). Phagocytosis: an immunobiologic process. Immunity 44, 463–475. doi: 10.1016/j.immuni.2016.02.026
Haeggström, J. Z., and Funk, C. D. (2011). Lipoxygenase and leukotriene pathways: biochemistry, Biology, and Roles in Disease. Chem. Rev. 111, 5866–5898. doi: 10.1021/cr200246d
Hansen, T. V., Dalli, J., and Serhan, C. N. (2017). The novel lipid mediator PD1n–3 DPA: an overview of the structural elucidation, synthesis, biosynthesis and bioactions. Prostaglandins Other Lipid Mediat. 133, 103–110. doi: 10.1016/j.prostaglandins.2017.06.003
Hong, S., Gronert, K., Devchand, P., Moussignac, R.-L., and Serhan, C. N. (2003). Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. 278, 14677–14687. doi: 10.1074/jbc.M300218200
Kasuga, K., Yang, R., Porter, T. F., Agrawal, N., Petasis, N. A., Irimia, D., et al. (2008). Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181, 8677–8687. doi: 10.4049/jimmunol.181.12.8677
Katakura, M., Hashimoto, H., Inoue, T., Mamun, A. A., Tanabe, Y., Arita, M., et al. (2015). Chronic arachidonic acid administration decreases Docosahexaenoic acid- and Eicosapentaenoic acid-derived metabolites in kidneys of aged rats. PLoS One 10:e0140884. doi: 10.1371/journal.pone.0140884
Körner, A., Schlegel, M., Theurer, J., Frohnmeyer, H., Adolph, M., Heijink, M., et al. (2018). Resolution of inflammation and sepsis survival are improved by dietary Omega-3 fatty acids. Cell Death Differ 25, 421–431. doi: 10.1038/cdd.2017.177
Kuda, O., Brezinova, M., Robaldova, M., Slavikova, B., Posta, M., Beier, P., et al. (2016). Docoshexaenoic acid-derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties. Diabetes Metab. Res. Rev. 65, 2580–2590. doi: 10.2337/db16-0385
Leonard, W. R. (2008). “Lifestyle, diet, and disease: comparative perspectives on the determinants of chronic health risks,” in Evolution in Health and Disease, 2nd Edn, eds S. C. Stearns and J. C. Koella (New York, NY: Oxford University Press), 265–276.
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., and Serhan, C. N. (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612–619. doi: 10.1038/89759
Levy, B. D., Kohli, P., Gotlinger, K., Haworth, O., Hong, S., Kazani, S., et al. (2007). Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J. Immunol. 178, 496–502. doi: 10.4049/jimmunol.178.1.496
Lopez-Vicario, C., Alcaraz-Quiles, J., Garcia-Alonso, V., Rius, B., Hwang, S. H., Titos E., et al. (2015). Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides. Proc. Natl. Acad. Sci. U.S.A. 112, 536–541. doi: 10.1073/pnas.1422590112
Malawista, S. E., de Boisfleury Chevance, A., van Damme, J., and Serhan, C. N. (2008). Tonic inhibition of chemotaxis in human plasma. Proc. Natl. Acad. Sci. U.S.A. 105, 17949–17954. doi: 10.1073/pnas.0802572105
Marcheselli, V. L., Mukherjee, P. K., Arita, M., Hong, S., Antony, R., Sheets, K., et al. (2010). Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 82, 27–34. doi: 10.1016/j.plefa.2009.10.010
Markworth, J. F., Kaur, G., Miller, E. G., Larsen, A. E., Sinclair, A. J., Maddipati, K. R., et al. (2016). Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid. FASEB J. 30, 3714–3725. doi: 10.1096/fj.201600360R
Mas, E., Croft, K. D., Zahra, P., Barden, A., and Mori, T. A. (2012). Resolvins D1, D2 and other mediators of self-limited resolution f inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58, 1476–1484. doi: 10.1373/clinchem.2012.190199
Masterson, J. C., McNamee, E. N., Fillon, S. A., Hosford, L., Harris, R., Fernando, S. D., et al. (2015). Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis. Gut 64, 1236–1247. doi: 10.1136/gutjnl-2014-306998
Medzhitov, R. (ed.) (2015). Innate Immunity and Inflammation. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
Miyata, J., Fukunaga, K., Iwamoto, R., Isobe, Y., Niimi, K., Takamiya, R., et al. (2013). Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J. Allergy Clin. Immunol. 131, 353–360. doi: 10.1016/j.jaci.2012.07.048
Morris, T., Stables, M., Hobbs, A., de Souza, P., Colville-Nash, P., Warner, T., et al. (2009). Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089–2096. doi: 10.4049/jimmunol.0900477
Murakami, M., Sato, H., Miki, Y., Yamamoto, K., and Taketomi, Y. (2015). A new era of secreted phospholipase A(2). J. Lipid Res. 56, 1248–1261. doi: 10.1194/jlr.R058123
Ogawa, N., and Kobayashi, Y. (2011). Total synthesis of the antiinflammatory and proresolving protectin D1. Tetrahedron Lett. 52, 3001–3004. doi: 10.1016/j.tetlet.2011.03.152
Oh, D. Y., and Olefsky, J. M. (2016). G protein coupled receptors as targets for anti-diabetic therapeutics. Nat. Rev. Drug Discov. 15, 161-172. doi: 10.1038/nrd.2015.4
Perretti, M. (2015). The resolution of inflammation: new mechanisms in patho-physiology open opportunities for pharmacology. Semin. Immunol. 27, 145–148. doi: 10.1016/j.smim.2015.06.001
Petasis, N. A., Akritopoulou-Zanze, I., Fokin, V. V., Bernasconi, G., Keledjian, R., Yang, R., et al. (2005). Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73, 301–321. doi: 10.1016/j.plefa.2005.05.020
Petasis, N. A., Yang, R., Winkler, J. W., Zhu, M., Uddin, J., Bazan, J. N. G., et al. (2012). Stereocontrolled total synthesis of neuroprotectin D1/protectin D1 and its aspirin-triggered stereoisomer. Tetrahedron Lett. 53, 1695–1698. doi: 10.1016/j.tetlet.2012.01.032
Pistorius, K., Souza, P. R., De Matteis, R., Austin-Williams, S., Primdahl, K. G., Vik, A., et al. (2018). PDn–3 DPA pathway regulates human monocyte differentiation and macrophage function. Cell Chem. Biol. 25, 749.e9–760.e9. doi: 10.1016/j.chembiol.2018.04.017
Primdahl, K. G., Tungen, J. E., De Souza, P. R. S., Colas, R. A., Dalli, J., Hansen, T. V., et al. (2017). Stereocontrolled synthesis and investigation of the biosynthetic transformations of 16(S),17(S)-epoxy-PDn–3 DPA. Org. Biomol. Chem. 15, 8606–8613. doi: 10.1039/c7ob02113e
Ramon, S., Dalli, J., Sanger, J. M., Winkler, J. W., Aursnes, M., Tungen, J. E., et al. (2016). The protectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation. Am. J. Pathol. 186, 962–973. doi: 10.1016/j.ajpath.2015.12.012
Rodriguez, A. R., and Spur, B. W. (2014). Total synthesis of the potent anti-inflammatory lipid mediator Protectin D1. Tetrahedron Lett. 55, 6011–6015. doi: 10.1016/j.tetlet.2014.09.007
Samuelsson, B. (2012). Role of basic science in the development of new medicines: examples from the eicosanoid field. J. Biol. Chem. 287, 10070–10080. doi: 10.1074/jbc.X112.351437
Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A., and Serhan, C. N. (1987). Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171–1176. doi: 10.1126/science.2820055
Serhan, C. N., and Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nat. Immun. 6, 1191–1197. doi: 10.1038/ni1276
Serhan, C. N. (1997). Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 53, 107–137. doi: 10.1016/S0090-6980(97)00001-4
Serhan, C. N. (2004). A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem. Cell Biol. 122, 305–321. doi: 10.1007/s00418-004-0695-8
Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92-101. doi: 10.1038/nature13479
Serhan, C. N. (2017). Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. 31, 1273–1288. doi: 10.1096/fj.201601222R
Serhan, C. N., and Chiang, N. (2013). Resolution phase lipid mediators of inflammation: agonists of resolution. Curr. Opin. Pharmacol. 13, 632–640. doi: 10.1016/j.coph.2013.05.012
Serhan, C. N., Chiang, N., and Dalli, J. (2015). The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin. Immunol. 27, 200–215. doi: 10.1016/j.smim.2015.03.004
Serhan, C. N., Fredman, G., Yang, R., Karamnov, S., Belayev, L. S., Bazan, N. G., et al. (2011). Novel proresolving aspirin-triggered DHA pathway. Chem. Biol. 18, 976–987. doi: 10.1016/j.chembiol.2011.06.008
Serhan, C. N., Gotlinger, K., Hong, S., Lu, Y., Siegelman, J., Baer, T., et al. (2006). Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176, 1848–1859. doi: 10.4049/jimmunol.176.3.1848
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., et al. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. 196, 1025–1037. doi: 10.1016/j.plefa.2009.10.010
Serhan, C. N., and Petasis, N. A. (2011). Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922–5943. doi: 10.1021/cr100396c
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., et al. (2009). Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J. Exp. Med. 206, 15–23. doi: 10.1084/jem.20081880
Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204.
Simopoulos, A. P. (2006). Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed. Pharmacother. 60, 502–507. doi: 10.1016/j.biopha.2006.07.080
Stein, K., Stoffels, M., Lysson, M., Schneiker, B., Dewald, O., Krönke, G., et al. (2016). A role for 12/15-lipoxygenase-derived proresolving mediators in postoperative ileus: protectin DX-regulated neutrophil extravasation. J. Leukoc. Biol. 99, 231–239. doi: 10.1189/jlb.3HI0515-189R
Tabas, I., and Glass, C. K. (2013). Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166–172. doi: 10.1126/science.1230720
Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998). Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 101, 819–826. doi: 10.1172/JCI1578
Tungen, J. E., Aursnes, M., Ramon, S., Colas, R. A., Serhan, C. N., Olberg, D., et al. (2018). Synthesis of protectin D1 analogs: novel pro-resolution and radiotracer agents. Org. Biomol. Chem. 16:6818-6823. doi: 10.1039/c8ob01232f
Tungen, J. E., Aursnes, M., Vik, A., Ramon, S., Colas, R., Dalli, J., et al. (2014). Synthesis and anti-inflammatory and pro-resolving activities of 22-OH-PD1, a monohydroxylated metabolite of protectin D1. J. Nat. Prod. 77, 2241–2248. doi: 10.1002/chem.201404721
Vane, J. R., and Botting, R. M. (2001). Therapeutic Roles of Selective COX-2 Inhibitors. London: William Harvey Press.
Vik, A., Dalli, J., and Hansen, T. V. (2017). Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid. Bioorg. Med. Chem. Lett. 27, 2259–2266. doi: 10.1016/j.bmcl.2017.03.079
Ward, P. A. (2010). Fundamentals of Inflammation, eds C. N. Serhan, P.A. Ward, and D. W. Gilroy, New York, NY: Cambridge University Press, 1–16.
White, P. J., Mitchell, P. L., Schwab, M., Trottier, J., Kang, J. X., Barbier, O., et al. (2015). Transgenic omega-3 PUFA enrichment alters morphology and gene expression profile in adipose tissue of obese mice: potential role for protectins. Metabolism 64, 666–676. doi: 10.1016/j.metabol.2015.01.017
White, P. J., St-Pierre, P., Charbonneau, A., Mitchell, P. L., St-Amand, E., Marcotte, B., et al. (2014). Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis. Nat. Med. 20, 664–669. doi: 10.1038/nm.3549
Keywords: protectins, specialized pro-resolving mediators, obesity, diabetes, G-protein coupled receptors, immunoresolvents, resolution pharmacology, western society diseases
Citation: Hansen TV, Vik A and Serhan CN (2019) The Protectin Family of Specialized Pro-resolving Mediators: Potent Immunoresolvents Enabling Innovative Approaches to Target Obesity and Diabetes. Front. Pharmacol. 9:1582. doi: 10.3389/fphar.2018.01582
Received: 02 October 2018; Accepted: 31 December 2018;
Published: 17 January 2019.
Edited by:
Lucy V. Norling, Queen Mary University of London, United KingdomReviewed by:
Hildur H. Arnardottir, Karolinska Institute (KI), SwedenSara Bonafini, University of Verona, Italy
Copyright © 2019 Hansen, Vik and Serhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Trond Vidar Hansen, dC52LmhhbnNlbkBmYXJtYXNpLnVpby5ubw==